Method to evaluate the dustiness of pharmaceutical powders

被引:41
|
作者
Boundy, Maryanne [1 ]
Leith, David
Polton, Thomas
机构
[1] Univ N Carolina, Dept Environm Sci & Engn, Chapel Hill, NC 27599 USA
[2] Pfizer Inc, New York, NY 10017 USA
来源
ANNALS OF OCCUPATIONAL HYGIENE | 2006年 / 50卷 / 05期
关键词
dustiness measurement; pharmaceuticals; toxic powders;
D O I
10.1093/annhyg/mel004
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
The trend among pharmaceutical companies to develop selective drugs of high potency has pushed the industry to consider the potential of each hazardous ingredient to become airborne. Dustiness issues are not unique to the pharmaceutical industry, but are relevant to any industry where powdered materials are mixed, transferred and handled. Interest in dustiness is also driven by concerns for worker health, the potential for plant explosions and the prevention of product loss. Unlike other industries, the pharmaceutical industry is limited by the milligram quantity of powdered material available for testing during product development. These needs have led to the development of a bench-top dustiness tester that requires only 10 mg of powder and fully contains the generated aerosol. The powder is dispersed within a 5.7 liter glass chamber that contains a respirable mass sampler and a closed-face sampler to quantify the respirable and total dust that are generated with a given energy input. The tester distinguished differences in dustiness levels of five different powders. Finer powders were dustier, and the respirable dust percentage was always less than that for total dust. Four testers have been built and evaluated using pharmaceutical grade lactose. Dustiness measurements determined using all four testers were comparable. The pharmaceutical industry uses surrogates such as lactose to represent active compounds in tests that estimate the dust concentration likely to occur in a new manufacturing operation. Differences between the dustiness of the active compound and its surrogate challenge the relevance of the surrogate tests to represent true exposures in the workplace. The tester can determine the dustiness of both the active compound and its surrogate, and the resultant ratio can help to interpret dust concentrations from surrogate tests. Further, dustiness information may allow the pharmaceutical researcher to select powder formulations that present low airborne concentrations in the workplace.
引用
收藏
页码:453 / 458
页数:6
相关论文
共 50 条
  • [21] A novel method to measure the glass and melting transitions of pharmaceutical powders
    Abiad, Mohamad G.
    Gonzalez, David C.
    Mert, Behic
    Campanella, Osvaldo H.
    Carvajal, M. Teresa
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2010, 396 (1-2) : 23 - 29
  • [22] An optical method for continuous monitoring of the dissolution rate of pharmaceutical powders
    Laitinen, Riikka
    Lahtinen, Jani
    Silfsten, Pertti
    Vartiainen, Erik
    Jarho, Pekka
    Ketolainen, Jarkko
    JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2010, 52 (02) : 181 - 189
  • [23] FLOWMETER FOR PHARMACEUTICAL POWDERS
    PITKIN, CG
    MITRA, AK
    PITKIN, CG
    JOURNAL OF PHARMACEUTICAL SCIENCES, 1973, 62 (04) : 693 - 693
  • [24] On the Relationship between Exposure to Particles and Dustiness during Handling of Powders in Industrial Settings
    Ribalta, Carla
    Viana, Mar
    Lopez-Lilao, Ana
    Estupina, Sara
    Cruz Minguillon, Maria
    Mendoza, Joan
    Diaz, Jordi
    Dahmann, Dirk
    Monfort, Eliseo
    ANNALS OF WORK EXPOSURES AND HEALTH, 2019, 63 (01) : 107 - 123
  • [25] COOLING AS A POSSIBLE METHOD FOR INCREASING THE FLOWABILITY OF CERTAIN PHARMACEUTICAL AND OTHER POWDERS
    ONYEKWELI, AO
    PILPEL, N
    JOURNAL OF PHARMACY AND PHARMACOLOGY, 1980, 32 (02) : 120 - 125
  • [26] MEASUREMENT OF ADHESIVE FORCE OF PHARMACEUTICAL POWDERS BY CENTRIFUGAL METHOD .I.
    OKADA, J
    MATSUDA, Y
    FUKUMORI, Y
    YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 1969, 89 (11): : 1539 - +
  • [27] Method for the realistic determination of the dustiness of bulk material
    Dahmann, D
    Hartfiel, GD
    Mocklinghoff, K
    GEFAHRSTOFFE REINHALTUNG DER LUFT, 1997, 57 (12): : 503 - 507
  • [28] Modelling the compaction behaviour of powders: application to pharmaceutical powders
    Michrafy, A
    Ringenbacher, D
    Tchoreloff, P
    POWDER TECHNOLOGY, 2002, 127 (03) : 257 - 266
  • [29] COMPACTION AND CONSOLIDATION OF PHARMACEUTICAL POWDERS
    FUHRER, C
    ACTA PHARMACEUTICA SUECICA, 1981, 18 (02): : 67 - 67
  • [30] CONTACT ANGLES OF PHARMACEUTICAL POWDERS
    LERK, CF
    LAGAS, M
    BOELSTRA, JP
    BROERSMA, P
    JOURNAL OF PHARMACEUTICAL SCIENCES, 1977, 66 (10) : 1480 - 1481